PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients

NCT04665830 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

OTHER_GOV

Sponsor class

Conditions

Kideny Transplant Recipients With High Cardiovascular Risk Score

Interventions

DRUG: Evolocumab

Sponsor

Hamid Al-Essa Organ Transplant Center